{"DataElement":{"publicId":"5946419","version":"1","preferredName":"Intraocular Route of Administration Therapeutic Procedure Administered Type","preferredDefinition":"A description of the intraocular therapy that was administered.","longName":"5944097v1.0:5944179v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"5944097","version":"1","preferredName":"Intraocular Route of Administration Therapeutic Procedure Administered","preferredDefinition":"Administration within the eye._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The act of having given something (e.g., a medication or test).","longName":"6029535v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"6029535","version":"1","preferredName":"Intraocular Route of Administration Therapeutic Procedure","preferredDefinition":"Administration within the eye.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"C38255:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intraocular Route of Administration","conceptCode":"C38255","definition":"Administration of a drug within the eye. Intraocular drugs are almost always used for their local effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E3065AA-8C6C-6517-E053-F662850AF759","latestVersionIndicator":"Yes","beginDate":"2017-11-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-17","modifiedBy":"ONEDATA","dateModified":"2017-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E79E2A-7245-31FE-E053-F662850A094F","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"NYCHM","dateModified":"2018-02-12","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5944179","version":"1","preferredName":"Intraocular Therapeutic Procedure Type","preferredDefinition":"Administration within the eye._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._Something distinguishable as an identifiable class based on common qualities.","longName":"5944179v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Intraocular rituximab","valueDescription":"Intraocular Route of Administration Rituximab","ValueMeaning":{"publicId":"5936030","version":"1","preferredName":"Intraocular Route of Administration Rituximab","longName":"5936030","preferredDefinition":"Administration within the eye.: A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intraocular Route of Administration","conceptCode":"C38255","definition":"Administration of a drug within the eye. Intraocular drugs are almost always used for their local effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57464E9E-A97F-49D8-E053-F662850AF627","latestVersionIndicator":"Yes","beginDate":"2017-08-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"57E8C4AF-01E1-0B04-E053-F662850AE020","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"ONEDATA","dateModified":"2017-08-29","deletedIndicator":"No"},{"value":"Intraocular methotrexate","valueDescription":"Intraocular Route of Administration Methotrexate","ValueMeaning":{"publicId":"5944544","version":"1","preferredName":"Intraocular Route of Administration Methotrexate","longName":"5944544","preferredDefinition":"Administration within the eye.: An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intraocular Route of Administration","conceptCode":"C38255","definition":"Administration of a drug within the eye. Intraocular drugs are almost always used for their local effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E8C4AF-0286-0B04-E053-F662850AE020","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F8A53F0-8FCD-04D6-E053-F662850A8F23","beginDate":"2017-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-04","modifiedBy":"ONEDATA","dateModified":"2017-12-04","deletedIndicator":"No"},{"value":"Other intraocular therapy","valueDescription":"Other Intraocular Route of Administration Therapeutic Procedure","ValueMeaning":{"publicId":"6051058","version":"1","preferredName":"Other Intraocular Route of Administration Therapeutic Procedure","longName":"6051058","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Administration within the eye.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Intraocular Route of Administration","conceptCode":"C38255","definition":"Administration of a drug within the eye. Intraocular drugs are almost always used for their local effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62983F74-7359-6FBC-E053-F662850A9E77","latestVersionIndicator":"Yes","beginDate":"2018-01-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62983F74-7374-6FBC-E053-F662850A9E77","beginDate":"2017-11-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-01-12","modifiedBy":"ONEDATA","dateModified":"2018-01-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6029547","version":"1","preferredName":"Intraocular Route of Administration Therapeutic Procedure Type","preferredDefinition":"Administration within the eye.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:Something distinguishable as an identifiable class based on common qualities.","longName":"C38255:C49236:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intraocular Route of Administration","conceptCode":"C38255","definition":"Administration of a drug within the eye. Intraocular drugs are almost always used for their local effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E30F39B-96E9-2CDB-E053-F662850A5B19","latestVersionIndicator":"Yes","beginDate":"2017-11-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-17","modifiedBy":"ONEDATA","dateModified":"2017-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E8621A-8537-7F1C-E053-F662850A390F","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"NYCHM","dateModified":"2018-02-12","changeDescription":".; Update PV \"Other therapy\" per OK to do so.  AK 1/12/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"LYMpost_OT_intraoc_drug_type","type":"NMDP_FN","context":"NHLBI"},{"name":"LYMpre_thrpym_intraoc_drug_ty","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify intraocular therapy","type":"Alternate Question Text","description":"Specify intraocular therapy","url":null,"context":"NHLBI"},{"name":"Specify intraocular therapy","type":"Application Standard Question Text","description":"Specify intraocular therapy","url":null,"context":"NHLBI"},{"name":"What was the intraocular ther","type":"Preferred Question Text","description":"What was the intraocular therapy that was administered?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"580EC750-3233-7A92-E053-F662850A0C84","latestVersionIndicator":"Yes","beginDate":"2017-08-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-31","modifiedBy":"NYCHM","dateModified":"2018-02-12","changeDescription":".; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}